



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated December 06, 2019

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Subject: - Clarification on presence of NDMA in Metformin manufactured by Granules India Limited

Dear Sir,

Granules India had received advise from the EU Health authorities to test for the presence of NDMA in metformin manufactured by the company. Granules had done a thorough risk assessment based on the route of synthesis used by it and had come to the conclusion that there is no possibility of the presence of NDMA in its product. This was informed to the EU authorities.

However the product is under analytical testing and preliminary results have shown that the impurity is absent. Further testing is ongoing and Granules will keep the EU authority updated.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For GRANULES INDIA LIMITED

Chaitanya Tummala


**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**